Comparative Pharmacology
Head-to-head clinical analysis: ELIXICON versus SLO BID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELIXICON versus SLO BID.
ELIXICON vs SLO-BID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Theophylline is a xanthine derivative that inhibits phosphodiesterase, leading to increased intracellular cyclic AMP levels. It also acts as a nonselective adenosine receptor antagonist, resulting in bronchodilation and anti-inflammatory effects.
Relaxes smooth muscle of bronchial airways and pulmonary blood vessels by inhibiting phosphodiesterase, increasing intracellular cAMP, and promoting bronchodilation.
400 mg orally every 6 hours or 600 mg orally every 8 hours; extended-release: 600-1200 mg orally every 12 hours.
Dose: 300-600 mg orally every 12 hours. Immediate-release: 5 mg/kg loading dose then 3 mg/kg every 6 hours. Extended-release: 10-15 mg/kg/day divided every 12 hours. Titrate to serum theophylline concentration of 5-15 mcg/mL.
None Documented
None Documented
Terminal elimination half-life: 4-6 hours in adults; 3-4 hours in children; prolonged in hepatic impairment or congestive heart failure. Context: dosing interval adjustment required in these conditions.
Terminal elimination half-life: 3-15 hours (mean ~10 hours in adults; 20-30 hours in neonates; 1-5 hours in smokers). Clinically, half-life decreases with smoking, increases with hepatic disease, heart failure, and certain drugs (e.g., cimetidine, ciprofloxacin).
Renal: 50% unchanged; hepatic metabolism to 3-methylxanthine, theophylline, etc. Biliary/fecal: minimal.
Renal: 90% as metabolites (caffeine, theobromine, paraxanthine, and unchanged drug; 1,3-dimethyluric acid, 1-methyluric acid, and 3-methylxanthine). Biliary/fecal: <10%.
Category C
Category C
Xanthine Bronchodilator
Xanthine Bronchodilator